Iqbal J. Hussain Sells 6,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

by · The Cerbat Gem

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $16.45, for a total value of $98,700.00. Following the completion of the sale, the general counsel now directly owns 105,386 shares of the company’s stock, valued at approximately $1,733,599.70. This represents a 5.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Centessa Pharmaceuticals Stock Performance

CNTA stock traded up $0.26 during midday trading on Wednesday, hitting $16.77. 627,614 shares of the company traded hands, compared to its average volume of 518,437. Centessa Pharmaceuticals plc has a twelve month low of $7.75 and a twelve month high of $19.09. The stock has a market capitalization of $2.21 billion, a price-to-earnings ratio of -10.96 and a beta of 1.54. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The business has a 50 day simple moving average of $16.45 and a 200-day simple moving average of $16.36.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Guggenheim reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. TD Cowen initiated coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating for the company. Finally, Morgan Stanley restated an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $26.00.

Check Out Our Latest Research Report on Centessa Pharmaceuticals

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC acquired a new stake in shares of Centessa Pharmaceuticals in the third quarter valued at about $2,834,000. Wellington Management Group LLP acquired a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at approximately $1,609,000. State Street Corp bought a new position in Centessa Pharmaceuticals in the 3rd quarter worth approximately $777,000. Ally Bridge Group NY LLC acquired a new position in shares of Centessa Pharmaceuticals during the third quarter worth approximately $4,951,000. Finally, Lord Abbett & CO. LLC bought a new stake in shares of Centessa Pharmaceuticals in the third quarter valued at approximately $4,305,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

(Get Free Report)

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

Further Reading